Bijuva

— THERAPEUTIC CATEGORIES —
  • Menopause and HRT

Bijuva Generic Name & Formulations

General Description

Estradiol, progesterone; 0.5mg/100mg, 1mg/100mg; caps.

Pharmacological Class

Estrogen + progestin.

How Supplied

Caps—30

Manufacturer

Generic Availability

NO

Bijuva Indications

Indications

Moderate to severe vasomotor symptoms due to menopause in women with a uterus.

Bijuva Dosage and Administration

Adult

Use lowest effective dose for the shortest duration. Take with food. Initially 0.5mg/100mg daily in the evening; adjust based on response. Attempt to taper or discontinue at 3–6 month intervals.

Children

Not applicable.

Bijuva Contraindications

Contraindications

Undiagnosed abnormal genital bleeding. Breast or other estrogen-dependent neoplasms. Active DVT, PE, or history of. Active arterial thromboembolic disease, or history of. Known hepatic impairment or disease. Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.

Bijuva Boxed Warnings

Boxed Warning

Cardiovascular disorders. Breast cancer. Endometrial cancer. Probable dementia.

Bijuva Warnings/Precautions

Warnings/Precautions

Not for prevention of cardiovascular disease or dementia. Increased risk of cardiovascular events (eg, MI, stroke, VTE); discontinue if occurs or suspected. Manage risk factors for cardiovascular disease and/or venous thromboembolism appropriately. Discontinue at least 4–6 weeks before surgery type associated with increased risk of thromboembolism or during prolonged immobilization. Increased risk of endometrial cancer in women with intact uterus (adding progestins has been shown to reduce endometrial hyperplasia risk). Breast or ovarian cancer. Risk of probable dementia in women ≥65yrs of age. Gallbladder disease. Severe hypercalcemia in breast cancer or bone metastases. Visual abnormalities. History of hypertriglyceridemia. Discontinue if cholestatic jaundice, pancreatitis, hypercalcemia, papilledema, or retinal vascular lesions occur. Monitor thyroid function. Conditions aggravated by fluid retention. Hypoparathyroidism. Endometriosis. Hereditary angioedema. Asthma. Diabetes. Epilepsy. Migraine. Porphyria. SLE. Hepatic hemangiomas. Perform yearly breast exams (including mammography). Reevaluate periodically. Elderly. Nursing mothers.

Bijuva Pharmacokinetics

See Literature

Bijuva Interactions

Interactions

May be potentiated by CYP3A4 inhibitors (eg, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, grapefruit juice). May be antagonized by CYP3A4 inducers (eg, phenobarbital, carbamazepine, rifampin, St. John's wort). Concomitant thyroid replacement; may need to increase thyroid dose. May interfere with lab tests (eg, thyroid, PT, coagulation factors, glucose tolerance, HDL/LDL, triglycerides, hormone concentrations, other binding or plasma proteins).

Bijuva Adverse Reactions

Adverse Reactions

Breast tenderness, headache, nausea, vaginal bleeding, vaginal discharge, pelvic pain; thromboembolism, neoplasms.

Bijuva Clinical Trials

See Literature

Bijuva Note

Not Applicable

Bijuva Patient Counseling

See Literature

Images